Skip to Main Content

Tara Sanft, MD

Associate Professor of Medicine (Medical Oncology); Chief, Patient Experience Officer; Medical Director, Survivorship Clinic

Research Summary

My research has centered around the patient experience during and after breast cancer treatment. I work with Melinda Irwin, PhD, MPH, Susan Dwight Bliss Professor of Epidemiology and Associate Dean of Research at the Yale School of Public Health.

Extensive Research Description

I conduct research with Dr. Melinda Irwin, and have completed several lifestyle intervention trials. I am the Principal Investigator of an NCI-funded R-01 study in which we randomize women to usual care or a healthy diet and exercise intervention in women undergoing chemotherapy for early stage breast cancer. We hope to find early intervention on lifestyle factors makes chemotherapy completion easier. Additionally, I am the site Principal Investigator of a study looking a resilience trajectories in patients diagnosed with breast, colon and prostate cancer, so that we may better learn who needs our help the most in order to thrive after cancer. I have mentored fellows on research projects including investigating decision-making for extended endocrine therapy in hormone receptor positive breast cancer; communication behaviors and patient experience during hospitalization on an oncology unit, exercise behaviors and chemotherapy completion rates and delivering survivorship education through an Enhancing Community Health Outcomes (ECHO) program.

Coauthors

Research Interests

Breast Diseases; Communication; Survivorship

Selected Publications

  • Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Nguyen T, Tanasijevic A, Tanasijevic A, Neuhouser M, Neuhouser M, Hershman D, Hershman D, Basen-Engquist K, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.
  • Ancillary treatment referrals and visits after breast cancer surgery in a sociodemographically diverse population.Chan V, Heller D, Berger E, Capozza S, Greenup R, Sanft T. Ancillary treatment referrals and visits after breast cancer surgery in a sociodemographically diverse population. Journal Of Clinical Oncology 2022, 40: 1533-1533. DOI: 10.1200/jco.2022.40.16_suppl.1533.
  • The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients.O'Shaughnessy J, Encarnacion C, O'Neal B, Wong J, Siuliukina N, Sanft T, Jankowitz R, Pegram M, Treuner K, Fox J. The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients. Journal Of Clinical Oncology 2022, 40: e12513-e12513. DOI: 10.1200/jco.2022.40.16_suppl.e12513.
  • 0590 Factors Associated with Sleep Health in Young Women After Breast Cancer TreatmentHwang Y, Conley S, Jeon S, Redeker N, Sanft T, Knobf M. 0590 Factors Associated with Sleep Health in Young Women After Breast Cancer Treatment Sleep 2022, 45: a259-a260. DOI: 10.1093/sleep/zsac079.587.
  • Abstract OT1-10-01: The Breast Cancer Index registry study: A prospective multi-center observational study to evaluate patient outcome, clinical impact, and medication adherence in HR+ breast cancer patients considering treatment with extended endocrine therapyO'Shaughnessy J, Fox J, Encarnación C, O'Neal B, Treuner K, Sanft T, Jankowitz R, Pegram M, Schnabel C, Diab S. Abstract OT1-10-01: The Breast Cancer Index registry study: A prospective multi-center observational study to evaluate patient outcome, clinical impact, and medication adherence in HR+ breast cancer patients considering treatment with extended endocrine therapy Cancer Research 2022, 82: ot1-10-01-ot1-10-01. DOI: 10.1158/1538-7445.sabcs21-ot1-10-01.
  • Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1Hurvitz S, Clark A, Rugo H, Bardia A, Zelnak A, Yardley D, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Purkayastha D, Eppig C, DeMichele A. Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1 Cancer Research 2022, 82: pd13-03-pd13-03. DOI: 10.1158/1538-7445.sabcs21-pd13-03.

Clinical Trials

ConditionsStudy Title
BreastAn Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Breast(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
BreastThe CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
BreastA Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Breast - Female; BreastTAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
BreastRandomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
BreastA Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)